Liu Minghao, Faez Iqbal Khan, Xiao Yuqing, Wang Xu, Hu Ziran, Lai Dakun
School of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu 610054, P. R. China.
School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, P. R. China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022 Oct 25;39(5):1005-1014. doi: 10.7507/1001-5515.202205021.
We aim to screen out the active components that may have therapeutic effect on coronavirus disease 2019 (COVID-19) from the severe and critical cases' prescriptions in the "Coronavirus Disease 2019 Diagnosis and Treatment Plan (Trial Ninth Edition)" issued by the National Health Commission of the People's Republic of China and explain its mechanism through the interactions with proteins. The ETCM database and SwissADME database were used to screen the active components contained in 25 traditional Chinese medicines in 3 prescriptions, and the PDB database was used to obtain the crystal structures of 4 proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molecular docking was performed using Autodock Vina and molecular dynamics simulations were performed using GROMACS. Binding energy results showed that 44 active ingredients including xambioona, gancaonin L, cynaroside, and baicalin showed good binding affinity with multiple targets of SARS-CoV-2, while molecular dynamics simulations analysis showed that xambioona bound more tightly to the nucleocapsid protein of SARS-CoV-2 and exerted a potent inhibitory effect. Modern technical methods are used to study the active components of traditional Chinese medicine and show that xambioona is an effective inhibitor of SARS-CoV-2 nucleocapsid protein, which provides a theoretical basis for the development of new anti-SARS-CoV-2 drugs and their treatment methods.
我们旨在从中华人民共和国国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第九版)》中重症和危重症病例的处方里筛选出可能对2019冠状病毒病(COVID-19)有治疗作用的活性成分,并通过与蛋白质的相互作用来解释其作用机制。利用中药系统药理学数据库(ETCM)和瑞士药物化学数据库(SwissADME)筛选3个处方中25味中药所含的活性成分,利用蛋白质数据银行(PDB)数据库获取严重急性呼吸综合征冠状病毒2(SARS-CoV-2)4种蛋白质的晶体结构。使用Autodock Vina进行分子对接,使用GROMACS进行分子动力学模拟。结合能结果显示,包括纤毛玉凤花皂苷、甘草宁L、木犀草苷和黄芩苷在内的44种活性成分与SARS-CoV-2的多个靶点表现出良好的结合亲和力,而分子动力学模拟分析表明纤毛玉凤花皂苷与SARS-CoV-2的核衣壳蛋白结合更紧密,并发挥了强大的抑制作用。运用现代技术方法研究中药活性成分表明,纤毛玉凤花皂苷是SARS-CoV-2核衣壳蛋白的有效抑制剂,为新型抗SARS-CoV-2药物及其治疗方法的开发提供了理论依据。